Breaking Finance News

Nivalis Therapeutics (NASDAQ:NVLS) stock price target reduced to $3.00, issued a research note today by Robert W. Baird

In a statement issued on Tuesday November 29, 2016 Robert W. Baird dropped the price target of Nivalis Therapeutics (NASDAQ:NVLS) from $29.00 to $3.00 indicating a possible downside of -0.52%.

On 7/13/2015, Stifel Nicolaus released a statement for Nivalis Therapeutics (NASDAQ:NVLS) raised the target price from $0.00 to $23.00. At the time, this indicated a possible upside of 0.33%.

Just yesterday Nivalis Therapeutics (NASDAQ:NVLS) traded -0.48% lower at $6.25. NVLS’s 50-day average is $6.46 and its two hundred day average is $5.84. With the last close up 7.04% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Volume of trade was down over the average, with 11,550 shares of NVLS changing hands under the typical 74,769

Recent Performance Chart

Nivalis Therapeutics (NASDAQ:NVLS)

Nivalis Therapeutics has 52 week low of $3.68 and a 52 week high of $9.45 and has a market capitalization of $0.

General Information About Nivalis Therapeutics (NASDAQ:NVLS)

Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *